On October 23, 2023 NanOlogy LLC, a clinical-stage oncology company, reported that an abstract has been accepted for poster presentation at the 38th Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) annual meeting being held November 1-5 at the San Diego Convention Center (Press release, NanOlogy, OCT 23, 2023, View Source;utm_medium=rss&utm_campaign=nanology-announces-an-abstract-has-been-accepted-for-presentation-at-the-38th-sitc-annual-meeting [SID1234636254]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The abstract (#1084) entitled: "Local administration of large surface area microparticle docetaxel is associated with anti-tumor immunomodulation across multiple tumor types" will be presented in Exhibit Hall B of the convention center during poster sessions throughout the day on Saturday, November 4th.

A press release summarizing presentation data will be issued following the conference.